KRAS Mutation Analysis
Also known as: KRAS G12, KRAS G12C, G12, G12C
Use
Mutations leading to amino acid substitutions in KRAS at codons 12, 13, 61, and 146 are among the most common alterations in human neoplasms. KRAS mutations are associated with poor prognosis and resistance to receptor tyrosine kinase–directed targeted therapies, including anti‑EGFR agents. KRAS is an emerging biomarker, notably including KRAS G12C, prevalent in non‑small cell lung cancer (~13% of patients, representing ~44% of KRAS mutations), and may inform prognosis and therapeutic options.
Special Instructions
Not provided.
Limitations
Not provided.
Methodology
NGS
Biomarkers
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Specimen
Tissue
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
Submission of formalin‑fixed, paraffin‑embedded tissue block is preferred; tissue source and block ID required on requisition; pathology report must accompany.
Other tests from different labs that may be relevant